Medication Errors: New EU Good Practice Guide on Risk Minimisation and Error Prevention.

Area of Science:

• Pharmacovigilance and Patient Safety
• Drug Development and Regulation

Background:

• Medication errors are unintended failures in drug treatment with potential for patient harm.
• The EU regulatory network introduced guidance in 2015 to address medication errors within pharmacovigilance legislation.
• Changes included redefining adverse reactions to encompass medication errors and enhancing collaboration between authorities.

Purpose of the Study:

• To describe the key concepts of the EU good practice guidance on medication errors.
• To support the pharmaceutical industry and regulators in implementing new pharmacovigilance legislation.
• To promote the safe and effective use of medicines.

Main Methods:

• The guidance distinguishes between various types of medication errors (e.g., with harm, without harm, intercepted, potential).
• Enhanced Medical Dictionary for Regulatory Activities (MedDRA®) terminology facilitates coding of errors and their consequences.
• Emphasis on root cause analysis and information gathering from individual case safety reports.

Main Results:

• A clear classification system for medication errors is established.
• Improved coding through enhanced MedDRA® terminology allows detailed analysis.
• Guidance promotes a lifecycle approach to risk minimization and prevention strategies.

Conclusions:

• The EU guidance provides a framework for defining, classifying, coding, reporting, evaluating, and preventing medication errors.
• Implementation of this guidance is expected to enhance patient safety and public health.
• Shared responsibility among patients, healthcare professionals, regulators, and industry is crucial for error reduction.